Association of polymorphisms of the TRIM21 gene with the severity of dry keratoconjunctivitis in rheumatoid arthritis and Sjogren's disease

Safonova, T N; Зайцева, Г. С.; Логинов, В. И.; Burdenniy, A M; Лукина, С. С.

doi:10.17116/oftalma2019135052192

Cited by 6 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A primary feature of SS is a systemic uncontrolled inflammation of exocrine tissues ( 18 , 19 ) thought to be initiated by viral and bacterial infection together with the activation of susceptibility genes ( 20 – 24 ). This leads to an initial tissue damage followed by cytokines and chemokine release ( 25 – 28 ) as well as exaggerated antibody production by hyperactivated B cells ( 7 , 18 , 19 ), all of which can be detected on exocrine tissues and serum ( 29 ).…”

Section: Introductionmentioning

confidence: 99%

Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren’s syndrome

Santos

Nam²,

Gil³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Sjögren’s syndrome is a chronic inflammatory autoimmune disease characterized by diminished secretory function of the exocrine glands. Although extensive investigation has been done to understand Sjögren’s syndrome, the causes of the disease are as yet unknown and treatments remain largely ineffective, with established therapeutic interventions being limited to use of saliva substitutes with modest effectiveness. A primary feature of Sjögren’s syndrome is uncontrolled inflammation of exocrine tissues and previous studies have demonstrated that lipid-based specialized pro-resolving mediators reduce inflammation and restores tissue integrity in salivary glands. However, these studies are limited to a single specialized pro-resolving lipid mediator’s family member resolvin D1 or RvD1 and its aspirin-triggered epimer, AT-RvD1. Consequently, additional studies are needed to explore the potential benefits of other members of the specialized pro-resolving lipid mediator’s family and related molecules (e.g., additional resolvin subtypes as well as lipoxins, maresins and protectins). In support of this goal, the current review aims to briefly describe the range of current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren’s syndrome, including both strengths and weaknesses of each approach where this information is known. With this article, the possibilities presented by specialized pro-resolving lipid mediators will be introduced to a wider audience in immunology and practical advice is given to researchers who may wish to take up this work.

show abstract